A127120 Stock Overview
A genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
DNA Link, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,160.00 |
| 52 Week High | ₩5,290.00 |
| 52 Week Low | ₩1,775.00 |
| Beta | 0.057 |
| 1 Month Change | 51.32% |
| 3 Month Change | 73.74% |
| 1 Year Change | 75.21% |
| 3 Year Change | 25.39% |
| 5 Year Change | 39.84% |
| Change since IPO | -70.85% |
Recent News & Updates
Recent updates
There's No Escaping DNA Link, Inc.'s (KOSDAQ:127120) Muted Revenues Despite A 27% Share Price Rise
Dec 04
DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For Growth
Jul 12There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is Undemanding
Mar 19Is DNA Link (KOSDAQ:127120) Using Too Much Debt?
Apr 19Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last Year
Feb 23Shareholder Returns
| A127120 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 22.9% | -1.2% | -0.9% |
| 1Y | 75.2% | 16.3% | -9.0% |
Return vs Industry: A127120 exceeded the KR Biotechs industry which returned 16.1% over the past year.
Return vs Market: A127120 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A127120 volatility | |
|---|---|
| A127120 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A127120 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A127120's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 81 | Jong-Eun Lee | dnalink.com |
DNA Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay.
DNA Link, Inc. Fundamentals Summary
| A127120 fundamental statistics | |
|---|---|
| Market cap | ₩116.02b |
| Earnings (TTM) | -₩11.31b |
| Revenue (TTM) | ₩19.04b |
6.1x
P/S Ratio-10.3x
P/E RatioIs A127120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A127120 income statement (TTM) | |
|---|---|
| Revenue | ₩19.04b |
| Cost of Revenue | ₩15.13b |
| Gross Profit | ₩3.92b |
| Other Expenses | ₩15.23b |
| Earnings | -₩11.31b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -503.21 |
| Gross Margin | 20.56% |
| Net Profit Margin | -59.42% |
| Debt/Equity Ratio | 49.8% |
How did A127120 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 15:38 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DNA Link, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Al Eum Lee | iM Securities |
| Sung Hwan Choi | Kyobo Securities Co., Ltd |
| Kidal Bae | Shinhan Investment Corp. |